A new case-based discussion from Dermatology Times, titled "Case 1: Assessing Severity and Barriers to Biologics in HS," turns attention to two persistent problems in hidradenitis suppurativa care: how clinicians grade disease severity at the point of care, and why patients who qualify for biologic therapy often do not receive it.

The case format puts those questions in a practical frame. Rather than reviewing trial data in the abstract, it walks through the decisions a clinician faces when an individual patient presents with symptomatic disease — which severity assessment to apply, what that assessment implies for treatment escalation, and what stands between the patient and a biologic prescription once the clinical rationale is established.

Severity assessment in HS remains less standardized than in psoriasis or atopic dermatitis, where validated instruments such as PASI and EASI anchor both clinical trials and everyday practice. HS lacks a single dominant endpoint of that kind. Clinicians typically rely on staging systems such as Hurley staging, together with lesion counts and measures of drainage and pain, to characterize burden. That heterogeneity matters clinically: the severity determination drives whether a patient is a candidate for systemic therapy, including the tumor necrosis factor-alpha inhibitor adalimumab and the interleukin-17 inhibitor secukinumab, both approved for moderate-to-severe disease.

The "barriers to biologics" half of the case speaks to a well-documented gap in HS management. Even after a clinician identifies a patient who meets criteria for advanced therapy, prior authorization requirements, payer documentation demands, cost, and delays in referral to dermatology can stall or block treatment initiation. HS disproportionately affects women and Black patients, and delayed access to effective therapy contributes to the progressive scarring and sinus tract formation that define advanced disease.

Case discussions of this type serve a distinct function in continuing education. They translate guideline recommendations — which generally position biologics for patients with moderate-to-severe HS inadequately controlled on conventional therapy — into the sequence of judgments that actually occurs in clinic: confirm the diagnosis, stage the disease, document failure or intolerance of first-line approaches, and build the record that supports payer approval.

The Dermatology Times piece is the first in what its labeling suggests is a series, indicating that subsequent cases may address follow-on questions such as biologic selection, dosing, response assessment, and management of patients who lose response over time.

For dermatologists, the practical takeaway is straightforward: rigorous, documented severity assessment is not an academic exercise in HS. It is the foundation for both appropriate escalation to biologic therapy and the authorization paperwork that determines whether that therapy reaches the patient.